Page values for "Lemborexant"
From Pharmacopedia
More actions
"Medicines" values
1 row is stored for this page| Field | Field type | Value |
|---|---|---|
| generic | String | |
| brand | String | Dayvigo |
| structure | File | |
| classes | List of String, delimiter: , | Dual orexin receptor antagonist (DORA) |
| mechanism | String | Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. |
| uses | String | Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019) |
| starting_dose | String | 5 mg PO at bedtime; may increase to 10 mg if inadequate |
| preparations | String | 5 mg, 10 mg tablets |
| fda_max | String | 10 mg/d |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | ~30 min |
| duration | String | ~7-8 hours |
| halflife | String | ~17-19 hours (longer than daridorexant) |
| bioavailability | String | ~44% |
| pregnancy | String | Limited data; avoid |
| legal | String | Rx, Schedule IV (US) |